These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
The second phase of an LGMD 2B study is looking for participantsRead more
The US Food and Drug Administration has granted Rare Paediatric Disease designation to MYO-101, for the treatment of LGMD 2E.
Researchers at University College London (UCL) have developed artificial ‘mini-muscles’ that could speed up testing potential treatments for muscle-wasting conditions.
Sarepta Therapeutics has announced it is partnering with Myonexus Therapeutics – a gene therapy company developing potential treatments for limb girdle muscular dystrophy (LGMD).
The US Food and Drug Administration has granted Orphan Drug Designation to MYO-101, for the treatment of limb girdle muscular dystrophy 2E.
An international study has found an association between exercise and symptom onset in people with dysferlinopathies (limb girdle muscular dystrophy type 2B and Miyoshi myopathy).
Myonexus Therapeutics has announced that it has secured $2.5 million to advance limb girdle muscular dystrophy (LGMD) gene therapies into the clinic.
A gene therapy has been shown to be safe and effective in treating mice with limb-girdle muscular dystrophy type 2E (LGMD2E).
We would like to inform you of a research study for adults with progressive muscle weakness caused by muscular dystrophy or inclusion body myositis (IBM).
A new biotechnology company called Myonexus Therapeutics is developing gene therapies for limb girdle muscular dystrophy (LGMD).
We are inviting you to join ACTMuS, a new study sponsored by King’s College Hospital and funded by the National Institute of Health Research and Muscular Dystrophy UK.